149 related articles for article (PubMed ID: 36209980)
1. Bacterial nanocellulose patches as a carrier for hydrating formulations to improve the topical treatment of nail diseases.
Bellmann T; Luber R; Kischio L; Karl B; Pötzinger Y; Beekmann U; Kralisch D; Wiegand C; Fischer D
Int J Pharm; 2022 Nov; 628():122267. PubMed ID: 36209980
[TBL] [Abstract][Full Text] [Related]
2. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
Subissi A; Monti D; Togni G; Mailland F
Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
[TBL] [Abstract][Full Text] [Related]
3. Development of ciclopirox nail lacquer with enhanced permeation and retention.
Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
[TBL] [Abstract][Full Text] [Related]
4. A drug-in-adhesive anti-onychomycotic nail patch: Influence of drug and adhesive nature on drug release, ungual permeation, in vivo residence in human and anti-fungal efficacy.
Rizi K; Xu K; Begum T; Faull J; Bhakta S; Murdan S
Int J Pharm; 2022 Feb; 614():121437. PubMed ID: 34973408
[TBL] [Abstract][Full Text] [Related]
5. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective.
Elsayed MM
J Control Release; 2015 Feb; 199():132-44. PubMed ID: 25481439
[TBL] [Abstract][Full Text] [Related]
6. A preformulation strategy for the selection of penetration enhancers for a transungual formulation.
Palliyil B; Lebo DB; Patel PR
AAPS PharmSciTech; 2013 Jun; 14(2):682-91. PubMed ID: 23572254
[TBL] [Abstract][Full Text] [Related]
7. Hydroxypropyl chitosan nail lacquer of ciclopirox-PLGA nanocapsules for augmented in vitro nail plate absorption and onychomycosis treatment.
Gaballah EY; Borg TM; Mohamed EA
Drug Deliv; 2022 Dec; 29(1):3304-3316. PubMed ID: 36372978
[TBL] [Abstract][Full Text] [Related]
8. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
9. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
Bohn M; Kraemer K
J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
[TBL] [Abstract][Full Text] [Related]
10. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis.
Khattab A; Shalaby S
AAPS PharmSciTech; 2018 Apr; 19(3):1048-1060. PubMed ID: 29138987
[TBL] [Abstract][Full Text] [Related]
11. Novel Drug Delivery Strategies for the Treatment of Onychomycosis.
Dhamoon RK; Popli H; Gupta M
Pharm Nanotechnol; 2019; 7(1):24-38. PubMed ID: 31092174
[TBL] [Abstract][Full Text] [Related]
12. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn M; Kraemer KT
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
[TBL] [Abstract][Full Text] [Related]
13. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
Hafeez F; Hui X; Selner M; Rosenthal B; Maibach H
Drug Dev Ind Pharm; 2014 Jun; 40(6):838-44. PubMed ID: 23600655
[TBL] [Abstract][Full Text] [Related]
14. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Gupta AK; Fleckman P; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
[TBL] [Abstract][Full Text] [Related]
15. Hydration of nail plate: a novel screening model for transungual drug permeation enhancers.
Chouhan P; Saini TR
Int J Pharm; 2012 Oct; 436(1-2):179-82. PubMed ID: 22705091
[TBL] [Abstract][Full Text] [Related]
16. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
McAuley WJ; Jones SA; Traynor MJ; Guesné S; Murdan S; Brown MB
Eur J Pharm Biopharm; 2016 May; 102():178-84. PubMed ID: 26969264
[TBL] [Abstract][Full Text] [Related]
17. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
[TBL] [Abstract][Full Text] [Related]
18. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
19.
Kubota-Ishida N; Takei-Masuda N; Kaneda K; Nagira Y; Chikada T; Nomoto M; Tabata Y; Takahata S; Maebashi K; Hui X; Maibach HI
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084749
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of the antifungal efficacy of poloxamer 407-based formulations in an infected nail plate model.
Täuber A; Müller-Goymann CC
Int J Pharm; 2016 May; 505(1-2):20-3. PubMed ID: 26992819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
